Is Sermorelin FDA Approved? FDA Withdrew the Approval in 2009

Last verified: 20 August 2026

Sermorelin is not an FDA-approved drug. It used to be. FDA withdrew the approval of both sermorelin new drug applications effective 18 June 2009, at the request of the company that held them, announcing it at 74 FR 23407 (19 May 2009). Seventeen years later it is the most widely sold peptide in the American telehealth market, appearing in the catalog of nearly every provider we have examined.

The industry's answer to "is sermorelin legal?" rests on one sentence: that sermorelin is a component of an FDA-approved drug, and is therefore compoundable under section 503A. We traced that claim to its source. It rests on a two-asterisk footnote in an FDA spreadsheet that appears to be out of date, in a document governing a different section of the statute, where the phrase it uses is not a legal pathway at all. We are reporting a documented inconsistency in FDA's own materials, not announcing a verdict — and we say plainly below what nobody, FDA included, has ever formally resolved.

If you are currently taking sermorelin, read this part first

This is not a safety alarm, and nothing here is a reason to stop a medication. Sermorelin has a longer and better-documented clinical history than almost any other peptide sold by telehealth companies. FDA did not pull it because people were hurt — the approval holder asked for the withdrawal, and in 2013 FDA formally determined it was not for reasons of safety or effectiveness (78 FR 14095, 4 March 2013).

What this is, is a disclosure problem. If you were told sermorelin is "FDA-approved" or "FDA-cleared," you were told something that is not accurate. If that would have changed your decision, raise it with the clinician who prescribed it. Ask which pharmacy compounds it, whether that pharmacy is a 503A pharmacy or a 503B outsourcing facility, and on which of the three statutory prongs they consider sermorelin eligible. A prescriber should be able to answer that.

The approval that genuinely existed

Sermorelin acetate is GHRH(1–29), the shortest fully active fragment of growth hormone-releasing hormone. It was marketed in the United States as GEREF, and it held two approvals:

This matters, and the peptide industry is right to point at it. Sermorelin is not a research chemical with no human history — it went through the full new drug application process twice and cleared it twice. Few substances in this market can say that.

The withdrawal, 2009

On 2 December 2008, EMD Serono wrote to FDA requesting withdrawal of the approval of its sermorelin applications. FDA granted it, publishing notice at 74 FR 23407 on 19 May 2009 in a bulk notice covering 92 NDAs and 49 ANDAs. The withdrawals took effect 18 June 2009.

Since 18 June 2009 there has been no approved sermorelin product in the United States. FDA's own commissioned literature review — prepared by the University of Maryland Center of Excellence in Regulatory Science and Innovation, December 2020 — says so in as many words:

"Sermorelin acetate is not available as an FDA-approved product."

The same report states that "there is no current United States Pharmacopeia (USP) monograph for sermorelin acetate" (UMB CERSI Summary Report, December 2020). Hold on to that second sentence — it closes the first of three doors.

What the 2013 determination did, and what it did not do

On 26 February 2013 FDA determined that GEREF was not withdrawn from sale for reasons of safety or effectiveness (78 FR 14095, 4 March 2013). This is cited constantly in sermorelin marketing, almost always implying it restored something. It did not.

The determination has one narrow function. When a drug is withdrawn from sale, FDA decides whether that was for safety or effectiveness reasons. If it was, the listing comes out of the Orange Book and no generic may reference it. If it was not, the product stays in the Discontinued Drug Product List and a generic manufacturer may file an ANDA referencing it.

An eligible reference listed drug is a target for a future generic application, not an approved product. No ANDA referencing GEREF has been approved, and we found no evidence one has been filed.

The three gates, and why sermorelin fails all of them

Compounding is not a general permission. Under 21 U.S.C. 353a(b)(1)(A)(i), a pharmacy may use a bulk drug substance only if it complies with an applicable USP or NF monograph, or is a component of a drug approved by the Secretary, or appears on the 503A Bulks List at 21 CFR 216.23. One of exactly three. Sermorelin clears none of them.

The third gate is worth spelling out, because this market discusses the bulks list as though it were long. As of the eCFR text current on 20 August 2026, 21 CFR 216.23 permits six substances — Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide, four of them topical only. The rule has not been amended since 84 FR 4710 (19 February 2019). There is not a peptide on it.

Sermorelin is not in any 503A category at all

Alongside the regulation, FDA maintains an interim policy sorting nominated bulk substances into three categories. Category 1 means FDA does not intend to take action against a compounder using the substance if the other conditions are met. Category 2 means FDA has identified significant safety risks. Category 3 means the nomination lacked sufficient information. None of these is law — Category 1 is enforcement intention, not a grant of legality.

We went through FDA's 503A nominations list as updated 14 May 2026 (FDA, 503A bulk drug substances). Sermorelin is not in Category 1, Category 2 or Category 3. It is not there at all.

That is a worse position than Category 2, not a better one, and the market has it backwards. A Category 2 substance at least sits inside a framework FDA has described. A substance nowhere in the framework has no enforcement-discretion policy attached to it in either direction.

The conflict in FDA's own documents — and what we are not claiming

Here is the evidence that cuts the other way — and it is the load-bearing citation in a great deal of sermorelin marketing. FDA's separate nominations list for 503B outsourcing facilities, updated 21 March 2025, carries an entry reading "Sermorelin Acetate**" in Category 1. The legend at the foot of that document reads:

"** Designates bulk drug substances that are components of FDA approved drugs."

That is FDA's document, on FDA's website (FDA 503B bulk drug substances nominations list). On its face it says sermorelin acetate is a component of an FDA-approved drug — irreconcilable with the 2009 withdrawal and with FDA's own 2020 commissioned report.

Our assessment — our inference, not FDA's position — is that the double asterisk is a stale legacy annotation never updated after the 2009 withdrawal. Two things support that reading.

First, the parallel case on the same list. The document also marks "Gonadorelin Acetate**", and gonadorelin's only US new drug application, NDA 019687 (Lutrepulse), is likewise discontinued. If the asterisk were maintained against current approval status, gonadorelin should not carry it either. Two entries with the same defect suggest an annotation that stopped being refreshed rather than a considered determination about each substance.

Second, the footnote is in the wrong document to mean what it is used to mean. "Component of an approved drug" is a prong of section 503A. It is not a pathway under 21 U.S.C. 353b, which governs outsourcing facilities and turns on FDA placing the substance on the 503B bulks list after a clinical-need determination, or on the drug being in shortage. A descriptive footnote in a 503B spreadsheet does not create a 503A eligibility finding, and FDA does not say it does.

503A and 503B are different, and the difference decides your bottle

A 503B outsourcing facility registers with FDA, is inspected against CGMP requirements, and is the entity FDA's Category 1 listing for sermorelin actually addresses. Even there, Category 1 is enforcement discretion rather than lawfulness, and sermorelin is not on the actual 503B bulks list — five substances, no peptides.

A 503A pharmacy compounds a patient-specific prescription for a named individual. That is the telehealth model exactly: you complete an intake, a clinician writes a prescription in your name, a pharmacy ships it to your door. That is the configuration with the problem, because section 503A and its three gates govern it — and our reading of the market is that nearly all telehealth sermorelin is dispensed by 503A pharmacies.

We did not confirm the registration status of every pharmacy named by every provider, and we will not assert that any specific pharmacy is or is not a registered outsourcing facility without checking. FDA publishes a registered outsourcing facility list, and anyone can look up the pharmacy named on their own shipment.

The evidence gap is a separate story, and it is just as important

Legality and evidence are independent axes. Sermorelin's regulatory problem and its evidence problem are different problems, and a substance can have one without the other.

Sermorelin has genuine, regulatory-grade human evidence — that is what two successful NDAs mean. But read what those approvals were for: assessment of pituitary growth hormone secretion, and idiopathic growth hormone deficiency in children. That evidence base is real, and it is narrow.

Sermorelin is now overwhelmingly prescribed for something else entirely — anti-aging, body composition, sleep quality, recovery, "natural growth hormone restoration" in adults who do not have growth hormone deficiency. We found no controlled trial evidence supporting any of those uses.

Here is what we searched and did not find. PubMed and Europe PMC, for controlled trials of sermorelin in healthy or aging adults with body-composition, lean-mass, sleep-quality or functional endpoints. ClinicalTrials.gov, for registered interventional studies outside pediatric growth hormone deficiency and diagnostic use. The FDA-commissioned CERSI report, the most recent agency-adjacent review of the substance we could locate. In none of those did we find a randomized controlled trial testing sermorelin against placebo for an anti-aging or wellness endpoint in adults. Every source asserting such an effect was a telehealth or vendor page citing no trial.

The absence is the finding. We are not saying sermorelin has been shown not to work for these purposes; we are saying that after looking where such evidence would be, we did not find it. In FTC terms, anti-aging and body-composition claims for sermorelin do not currently appear to rest on competent and reliable scientific evidence.

Anti-doping: a third, entirely separate axis

If you compete under the World Anti-Doping Code, none of the above matters to your eligibility. Sermorelin is explicitly named in WADA S2.2.4, Growth Hormone Releasing Factors, alongside CJC-1293, CJC-1295 and tesamorelin. S2 substances are prohibited at all times.

The point consumer peptide content almost never makes: a prohibited substance does not become permitted because it was lawfully prescribed. Tesamorelin is a fully FDA-approved drug and is prohibited in sport. Sermorelin is prohibited whether it reaches you through a pharmacy or any other route, and a prescription is not a therapeutic use exemption. Legality and doping status are independent axes; being right about one tells you nothing about the other. (We could not verify the current List's effective date directly — wada-ama.org blocks automated retrieval and the mirror we read S2.2.4 from carries no version stamp. Athletes should confirm against the current List.)

What providers charge, as of 20 August 2026

All prices below were read from each company's own public pages on 20 August 2026 unless noted. Prices here move; undated prices are worthless.

Embody, Lttl and Luvo Health each name the same clinical partner and the same four compounding pharmacies in their own published documents — RedRock, Health Warehouse, Precision Compounding and Triad Rx. Their listed sermorelin prices on 20 August 2026 ranged from $99 to $199. The document-by-document detail is in Same pharmacy, three prices.

Note what the money buys. If our reading of section 503A is right, the difference is not a different product, a better product, or a more lawful product — it is the same compounded substance from the same facilities through a different brand.

Where this leaves things

Our reading is that the three gates close and the footnote is stale. We hold that as a reading rather than a holding, because FDA has not decided the question and neither has a court. What is not in dispute — and what anyone can verify in the Federal Register in a minute — is the fact at the top of this article: the approval was withdrawn on 18 June 2009, and nothing since has brought it back.

Frequently asked questions

Is sermorelin FDA approved?

No. It was approved as GEREF under NDA 19-863 (1990) and NDA 20-443 (1997), and FDA withdrew both effective 18 June 2009 at the holder's request (74 FR 23407). There is no approved sermorelin product in the United States today, and FDA's own commissioned 2020 report says so.

Is sermorelin legal?

Legality here has gates and the honest answer names them. Being prescribed sermorelin is not a criminal matter for a patient. The unresolved question is whether a 503A pharmacy may lawfully compound it. To do that, the substance must satisfy one of three conditions in 21 U.S.C. 353a(b)(1)(A)(i): a USP monograph, being a component of an approved drug, or appearing on the 503A Bulks List at 21 CFR 216.23. On our reading it satisfies none of the three. FDA has never published a determination on whether a withdrawn approval counts for the second prong, and we found no case law on it.

Why do so many clinics say sermorelin is a component of an FDA-approved drug?

That claim traces to a double-asterisk footnote on FDA's 503B nominations list (updated 21 March 2025), which designates certain substances as components of FDA-approved drugs and applies that mark to sermorelin acetate. Our assessment, labeled as our inference, is that the annotation is stale and was not updated after the 2009 withdrawal. The same list carries the identical mark on gonadorelin acetate, whose only NDA is likewise discontinued, and the footnote appears in a document governing 503B outsourcing facilities, where "component of an approved drug" is not a statutory pathway.

Didn't FDA reinstate sermorelin in 2013?

No. The 26 February 2013 determination (78 FR 14095) found only that GEREF was not withdrawn for reasons of safety or effectiveness. Its effect is to keep the product in the Orange Book Discontinued Drug Product List so that generic applicants may reference it. It does not reinstate an approval, and no generic sermorelin has been approved.

Is sermorelin safe?

FDA did not withdraw sermorelin for safety reasons and confirmed as much in 2013. It is the best-characterized of the growth hormone secretagogues precisely because it went through the approval process. That is not the same as being well studied for how it is used today: the class-level concern with sustained elevation of growth hormone and IGF-1 has not been tested in long-term trials of sermorelin in healthy adults. Compounded product also carries the ordinary risks around potency and sterility, which vary by pharmacy.

Should I stop taking sermorelin?

That is a decision for you and your prescriber. Nothing here is a safety warning. Our finding is about disclosure: if you were told the substance is FDA-approved, that is not correct, and it is worth raising with whoever told you.

Can I take sermorelin if I compete in sport?

No. Sermorelin is explicitly named in WADA S2.2.4 and prohibited at all times, including where lawfully prescribed. A prescription is not a therapeutic use exemption.

This is consumer research about how peptides are regulated and sold. It is not medical advice, and we are not your doctor. Nothing here should be used to start, stop or change any treatment. Talk to a licensed clinician who knows your history.